und den ursprünglichen Hinweis auf diese Aktie würde ich Calibra21 gerne einen grünen Stern schenken. Was muss ic dazu machen?
Anzeige
Meldung des Tages: KI für Verteidigung! Der Countdown zu einer der heißesten AI-Hightech-Stories 2026 beginnt jetzt
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 5 6 7 8 9 10 12 13
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 5 6 7 8 9 10 12 13
$$ Grant Life Sciences! Volumen lügt nicht! $$
Werbung
Passende Knock-Outs auf DAX
| Strategie | Hebel | |||
| Steigender DAX-Kurs | 5,00 | 9,98 | 15,00 | |
| Fallender DAX-Kurs | 5,01 | 10,08 | 15,01 | |
Den Basisprospekt sowie die Endgültigen Bedingungen finden Sie jeweils hier: DE000VK81Q13
, DE000VJ29D16
, DE000VH9YXE0
, DE000VH63G46
, DE000VH8NX95
, DE000VG58BK3
.Bitte informieren Sie sich vor Erwerb ausführlich über Funktionsweise und Risiken. Bitte beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Beiträge:
307
Zugriffe: 38.698 / Heute: 1
Zugriffe: 38.698 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
du bist noch nicht lange genug dabei.
Greetings
Overall§ Short Intermediate Long
Bullish (0.35) Bullish (0.33) Bullish (0.45) Bullish (0.28)
viel Glück
Overall§ Short Intermediate Long
Bullish (0.35) Bullish (0.33) Bullish (0.45) Bullish (0.28)
viel Glück
(Verkleinert auf 85%) 
ich hab probleme mit WO LINK
????????????????ßß
????????????????ßß
kommen, nach diesem super Kursanstieg
mfg
mfg
Last Sale $ 0.233
Change Net / % 0.018 8.37%
Best Bid / Ask $ 0.23 / $ 0.233
Change Net / % 0.018 8.37%
Best Bid / Ask $ 0.23 / $ 0.233
,dass die Gewinnmitnahmen nach dem großen Kursanstieg letzte Woche doch sehr moderat ausgefallen sind.. ich finde das ist ein sehr gutes Zeichen...
um die hohe Market-cap zu rechtfertigen. Ich hoffe es kommen bald gute News!
Grant Life Sciences and Diagnostic Technologies Ltd. Are Exploring an Expanded Partnership beyond Their Initially Proposed Association to Develop and Commercialize Grant's Cervical Cancer-Diagnostic Platform
biz.yahoo.com/bw/061027/20061027005530.html?.v=1
Die Vereinbarungen mit DTL scheinen zugunsten glif's erweitert worden zu sein. Hoffentlich kommen "zu gegebener Zeit" konkrete Ergebnisse.
biz.yahoo.com/bw/061027/20061027005530.html?.v=1
Die Vereinbarungen mit DTL scheinen zugunsten glif's erweitert worden zu sein. Hoffentlich kommen "zu gegebener Zeit" konkrete Ergebnisse.
die von Dir angeführten Kursziele(z.B 0,38)?
Die Konsolidierung des Wertes nach dem grossen Anstieg von Anfang Oktober schon langsam überwunden zu sein.. Langsam geht es wieder bergauf...und das Volumen steigt auch langsam wieder an...
kann man nicht "langsam" nennen. Schaut euch das hohe Volumen bei den Amis an. Da wirds´s morgen Früh bei uns wieder teure Einstiegskurse geben.
als ich gepostet hab waren wir noch bei 8% + da war´s noch langsam...
Aber mal abwarten wo wir morgen einsteigen...
Gruss
Aber mal abwarten wo wir morgen einsteigen...
Gruss
Gelöschter Beitrag.
Einblenden
»
#267
gestern wieder wieder ein gewaltige Plus. Nach Börsenschluss kamen die News.
Bin schon auf heute gespannt.
Press Release Source: Grant Life Sciences
Grant Life Sciences hires Kim Liao as Director of Asian Business Development
Wednesday December 6, 1:50 pm ET
Previously held senior executive positions with Abbott Laboratories Service Corp.'s Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide (Taiwan)
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences ('Grant') Inc. (OTC BB: GLIF - News) announced today that it has hired Mr. Kim Liao as director of Asian business development, effective immediately.
ADVERTISEMENT
"We are extremely pleased to have such an accomplished industry executive as Kim Liao join Grant Life Sciences, particularly in light of his significant 'hands on' experience in the markets of Taiwan, China and Singapore," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "Certainly, Kim will play a key role in executing Grant's new corporate strategy: (1) acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels. Kim will oversee development of Grant's expansion into Asia, including the structuring of clinical trials for our HPV-DNA tests at United Clinical Lab (the largest reference lab in Taiwan} and National Taiwan University's Medical Center. In short, Kim will be spearheading the commercialization of Grant's products from clinical acceptance to sales in new, key Asian markets."
Between 1995 and 2006, Kim Liao held a variety of executive positions with increasing responsibilities in the areas of sales, product management and general management with Abbott Laboratories Services Corp.'s Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide (Taiwan). He holds a master's degree in microbiology from California State University (Fullerton) as well as numerous certifications in pathology and clinical laboratory technology.
About Grant Life Sciences Inc.
Grant Life Sciences, a development stage company, engages in research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact:
Grant Life Sciences Inc.
Don Rutherford, CFO, 949-521-1232
Bin schon auf heute gespannt.
Press Release Source: Grant Life Sciences
Grant Life Sciences hires Kim Liao as Director of Asian Business Development
Wednesday December 6, 1:50 pm ET
Previously held senior executive positions with Abbott Laboratories Service Corp.'s Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide (Taiwan)
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences ('Grant') Inc. (OTC BB: GLIF - News) announced today that it has hired Mr. Kim Liao as director of Asian business development, effective immediately.
ADVERTISEMENT
"We are extremely pleased to have such an accomplished industry executive as Kim Liao join Grant Life Sciences, particularly in light of his significant 'hands on' experience in the markets of Taiwan, China and Singapore," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "Certainly, Kim will play a key role in executing Grant's new corporate strategy: (1) acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels. Kim will oversee development of Grant's expansion into Asia, including the structuring of clinical trials for our HPV-DNA tests at United Clinical Lab (the largest reference lab in Taiwan} and National Taiwan University's Medical Center. In short, Kim will be spearheading the commercialization of Grant's products from clinical acceptance to sales in new, key Asian markets."
Between 1995 and 2006, Kim Liao held a variety of executive positions with increasing responsibilities in the areas of sales, product management and general management with Abbott Laboratories Services Corp.'s Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide (Taiwan). He holds a master's degree in microbiology from California State University (Fullerton) as well as numerous certifications in pathology and clinical laboratory technology.
About Grant Life Sciences Inc.
Grant Life Sciences, a development stage company, engages in research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact:
Grant Life Sciences Inc.
Don Rutherford, CFO, 949-521-1232
Habe ich hier gefunde
home.tiscali.de/chartcheck/
mit kostenlosem Newsletter!
home.tiscali.de/chartcheck/
mit kostenlosem Newsletter!
Sieht nach einer Gegenreaktion aus!
Schätze könnte bis 10ct laufen!
Oder es kommt was auf uns zu...
Nur meine Meinung
---------------------
Alles wird gut..!!!
Schätze könnte bis 10ct laufen!
Oder es kommt was auf uns zu...
Nur meine Meinung
---------------------
Alles wird gut..!!!
Auf ein neues
[@img http://www.cheesebuerger.de/smiliegenerator/ablage/310/73.png]
[@img http://www.cheesebuerger.de/smiliegenerator/ablage/310/73.png]
damit du nicht ganz alleine im Thread bist und immer neu lustig Dinge ausprobieren musst.
Frohe Weihnachten
Frohe Weihnachten
Es gibt keine neuen Beiträge.
|
![http://www.cheesebuerger.de/smiliegenerator/ablage/310/73.png]](http://www.cheesebuerger.de/smiliegenerator/ablage/310/73.png]){kind=link}
Werbung
Passende Knock-Outs auf DAX
| Strategie | Hebel | |||
| Steigender DAX-Kurs | 5,00 | 9,98 | 15,00 | |
| Fallender DAX-Kurs | 5,01 | 10,08 | 15,01 | |
Den Basisprospekt sowie die Endgültigen Bedingungen finden Sie jeweils hier: DE000VK81Q13
, DE000VJ29D16
, DE000VH9YXE0
, DE000VH63G46
, DE000VH8NX95
, DE000VG58BK3
.Bitte informieren Sie sich vor Erwerb ausführlich über Funktionsweise und Risiken. Bitte beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Neueste Beiträge aus dem GRANT LIFE SCIENCES Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
15 | 306 | $$ Grant Life Sciences! Volumen lügt nicht! $$ | Calibra21 | hershel | 22.10.09 12:48 | |
| 7 | $GLIF$ Die Wiedergeburt ? | Canon | tomboe | 13.11.07 23:10 | ||
| 1 | vorsicht | consors | HausmeisterKrause | 14.07.06 09:19 | ||
| 22 | $$ Grant Life $$ +53 % $$ | flumi4 | Calibra21 | 12.04.06 19:14 | ||
| 17 | Wer ist dabei? | micha1 | azel | 21.12.05 15:37 |